Arcan's Insight® 100 Ultrasound Approved in China

ArcScan, a global medical technology company dedicated to revolutionizing ophthalmic care, marked a significant milestone with the announcement of the National Medical Products Administration (NMPA) approval of its flagship product, the ArcScan Insight® 100, for use in China.

Addressing the Myopia Epidemic

"We believe the ArcScan Insight® 100 will help eyecare surgeons in China to better address the myopia epidemic which is predicted to affect 5 billion people globally by 2050 according to the journal Ophthalmology," stated Andrew Levien, ArcScan CEO, emphasizing the potential impact of the approval.

The Insight® 100, surpassing the limitations of optical coherence tomography (OCT), offers comprehensive visualization of the anterior segment, aiding surgeons in identifying anatomical artifacts crucial for achieving optimal post-surgical outcomes

Accurate Sizing for Myopia Treatment

"Using Insight® 100, eye surgeons can more accurately determine the appropriate sizing of phakic intraocular lenses (pIOL’s) for placement behind the iris for treatment of myopia, commonly known as nearsightedness," Levien added.

The approval comes at a critical time, with myopia rates on the rise globally. According to the 2024 Global IOL Market Report by Market Scope Reports, phakic IOL procedures are projected to experience substantial growth, reaching over 780 thousand procedures globally in 2024 alone.

Improved Patient Outcomes

"The Insight® 100 has significantly improved outcomes for my patients," shared Robert Lin, MD, founder and CEO of IQ Laser Vision, California, emphasizing the positive impact of the technology on patient care.

ArcScan Insight® 100 is a computer-controlled high-frequency ultrasound device providing precise, detailed images of the anterior segment of the eye. The device has received FDA marketing clearance, CE approval, and now NMPA Certification, underscoring its global recognition and applicability in enhancing ophthalmic care.

"Applications continue to grow, complementing OCT limitations with precision ultrasonic imaging behind the iris," highlighted the statement. ArcScan, Inc., headquartered in Denver, Colorado, boasts 19 patents surrounding its unique approach to ophthalmic imaging, with ongoing efforts to expand its applications and further contribute to the field of eye health.

About Myopia

Myopia, commonly known as nearsightedness, is a refractive error of the eye where distant objects appear blurry while close objects remain clear. It occurs when the eyeball is too long or the cornea is too curved, causing light rays to focus in front of the retina rather than directly on it. Myopia is a prevalent condition worldwide, with its prevalence increasing dramatically in recent years, particularly in urbanized areas and among younger populations.

Factors such as genetics, prolonged near-work activities, and limited outdoor exposure have been linked to the development and progression of myopia. Left uncorrected, myopia can lead to visual discomfort, difficulty in daily activities, and an increased risk of eye diseases such as retinal detachment, glaucoma, and myopic maculopathy.